The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease

Background: Mosapride is a novel prokinetic agent facilitating acetylcholine release from the enteric cholinergic neurones through a selective 5‐HT4 receptor agonistic action. It is also active through its main metabolite M1, which is a 5‐HT3 antagonist. The importance of motor dysfunction in the pa...

Ausführliche Beschreibung